Back

Notification report


Full notification file


General information

Notification Number
B/DE/20/PEI3860

Member State to which the notification was sent
Germany

Date of acknowledgement from the Member State Competent Authority
29/08/2019

Title of the Project
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)

Proposed period of release:
10/01/2020 to 30/06/2020

Name of the Institute(s) or Company(ies)
Pfizer, Inc., 235 East 42nd Street, New York, NY 10017-5755, USA.;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
France; United Kingdom; Greece; Sweden;

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Genus: Dependoparvovirus
Species: AAVSpark100 - bioengineered adeno-associated viral vector derived from a naturally occurring AAV serotype


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
-DependoparvovirusAdeno-associated Virus-AAV-Spark100-

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
17/04/2020 00:00:00
Remarks: